Effects of eplerenone on cerebral aldosterone levels and brain lesions in spontaneously hypertensive rats
| Autor: | Haonan Sun, Xue Wang, Wei Yao, Yuhai Zhu, Shuanglin Wang, Yujie He, Zhuoqun Wang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
2019-20 coronavirus outbreak medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Physiology Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Apoptosis Aldosterone levels Disease 030204 cardiovascular system & hematology Spironolactone Renin-Angiotensin System 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Rats Inbred SHR Internal Medicine Medicine Animals 030212 general & internal medicine Aldosterone Antihypertensive Agents Mineralocorticoid Receptor Antagonists business.industry food and beverages Brain General Medicine Eplerenone Rats Endocrinology Treatment Outcome chemistry Hypertension Brain lesions business medicine.drug |
| Zdroj: | Clinical and experimental hypertension (New York, N.Y. : 1993). 42(6) |
| ISSN: | 1525-6006 |
| Popis: | Evidence indicates that renin-angiotensin-aldosterone system (RAS) inhibitors can protect the brain in Alzheimer's disease and Parkinson's disease. The current study evaluated the relationship between aldosterone and tissue damage in the brains of spontaneously hypertensive rats (SHRs) and whether the RAS inhibitor eplerenone can mitigate the damage seen in these rats. SHRs were randomly divided into eplerenone (n = 10) and SHR (n = 10) groups, and Wistar-Kyoto (WKY) rats (n = 10) were used as controls. Eplerenone 50 mg/kg/day was administered orally to the eplerenone group. Pathological changes to the hippocampal formation, plasma and encephalic aldosterone, and plasma potassium levels were compared among the groups. After 10 weeks, rats in the eplerenone and SHR groups showed higher systolic BP ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|